Neovascular age-related macular degeneration (NAMD)
Clinical trials for Neovascular age-related macular degeneration (NAMD) explained in plain language.
Never miss a new study
Get alerted when new Neovascular age-related macular degeneration (NAMD) trials appear
Sign up with your email to follow new studies for Neovascular age-related macular degeneration (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
One eye injection, four targets: GenSci148 tested against retinal swelling
Disease control Not yet recruitingResearchers are testing an experimental eye injection called GenSci148 in people with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). GenSci148 is a fusion protein designed to block four proteins involved in blo…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase 1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a new eye injection beat the standard for wet AMD?
Disease control Not yet recruitingThis trial tests an experimental drug called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. Researchers compare two doses of VIS-101 against aflibercept, a standard treatment, to see if VIS-…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase 2 • Sponsor: Everest Medicines (China) Co.,Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Laser zap before eye injection could cut needle count for wet AMD
Disease control Not yet recruitingThis study tests whether a low-intensity laser applied to the diseased area just before an anti-VEGF injection helps the drug work better in people with wet age-related macular degeneration (AMD). Wet AMD causes abnormal blood vessels to leak fluid under the retina, and current t…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New eye drug faricimab tested for blinding disease
Disease control Not yet recruitingThis study will test the drug faricimab, given as eye injections, in 50 people with wet age-related macular degeneration (nAMD). The goal is to see if it improves vision and eye health. Participants will receive 4 initial doses, then more as needed. The study is observational, me…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New eye drug aims to match leading treatment for blinding disease
Disease control Not yet recruitingThis phase 3 trial tests whether a new drug, QL1207H, works as well as the standard treatment Eylea for wet age-related macular degeneration, a leading cause of vision loss. About 356 adults aged 50 and older with active disease will receive injections every 4 weeks for 3 doses, …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New eye drug GB10 enters early human testing for wet AMD
Disease control Not yet recruitingThis early-stage trial tests a new drug called GB10, given as an eye injection, for people with wet age-related macular degeneration (AMD). The study will include 48 participants and aims to check safety and find the right dose. It is not yet recruiting and is too early to know i…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase 1 • Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Could a cotton swab replace the metal speculum for eye injections?
Symptom relief Not yet recruitingThis study tests if using a cotton-tipped applicator to hold the eyelid open during eye injections is less painful and faster than the standard metal speculum. About 120 adults with certain eye conditions will take part. The goal is to improve comfort and satisfaction without com…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Jakkrit Juhong • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC